PYC Therapeutics
PYC Therapeutics is a clinical-stage biotech company focused on developing RNA therapies to address genetic diseases. Their proprietary RNA delivery platform aims to provide safer and more effective treatments by targeting the underlying causes of these diseases. The company is advancing a pipeline of novel therapies for eye, central nervous system, and kidney diseases.
Short position
PYC Therapeutics (ASX:PYC) has 0.82% of its shares on issue reported as short positions as of 5 Oct 2026, or about 8,063,670 shares. Over the past 30 days that figure has risen 0.79 percentage points, and over 90 days it has risen 0.48 percentage points. Its highest recorded short interest was 1.09% in September 2026. PYC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PYC Therapeutics (PYC) company profile
Profile, insiders and operations
Company
AI-generated research profile of Pyc Therapeutics
Operations exposure
Western AustraliaMajority of operations (estimate)
Basis: Perth-based biotech R&D operations
Coarse bands are AI estimates based on public company information.
PYC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links